INmune Bio (INMB) said Monday it closed the enrollment of a phase 2 trial involving patients with early Alzheimer's Disease and elevated neuroinflammation.
INmune said it determined that they've enrolled enough patients to meet the study's target of 201 individuals, which will be evaluated with the company's investigational XPro treatment.
Price: 5.50, Change: +0.28, Percent Change: +5.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.